TITLE

Plavix Granted Additional Exclusivity

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p50
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the announcement of Bristol-Myers Squibb co. and Sanofi-Aventis SA that the Food and Drug Administration (FDA) has granted them additional six-month period of exclusivity in marketing Plavix (clopidogrel bisulfate) for adult patients with acute coronary syndrome in the U.S.
ACCESSION #
59994629

 

Related Articles

  • SANOFI.  // Contract Pharma;Jul/Aug2012, Vol. 14 Issue 6, p52 

    The article profiles Sanofi located in Paris, France, the number three company in the list of the top 20 pharma in the July/August 2012 issue of the journal "Contract Pharma." It says that the patent protection for Plavix was lost by Sanofi in most markets in 2012 and gained around 1.8 billion...

  • Writing with Conviction. Silverman, Ed // Contract Pharma;Jun2012, Vol. 14 Issue 5, p32 

    The article focuses on the role of Andrew Bodnar, a former senior vice president at Bristol-Myers Squibb Co. (BMS), in the negotiations between BMS, marketing partner Sanofi-Aventis SA, and generic marketer Apotex Inc. to keep a generic version of best-selling blood thinner Plavix off the...

  • OTC Pharmaceuticals Industry Profile: France.  // OTC Pharmaceuticals Industry Profile: France;Oct2005, p1 

    Presents a profile of the OTC Pharmaceuticals industry in France. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • OTC Pharmaceuticals Industry Profile: France.  // OTC Pharmaceuticals Industry Profile: France;Dec2006, p1 

    Presents a profile of the OTC Pharmaceuticals industry in France. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • New drugs and dosage forms. Traynor, Kate // American Journal of Health-System Pharmacy;12/1/2006, Vol. 63 Issue 23, p2284 

    A list of drugs and dosage forms is presented. Atazanavir sulfate capsules are manufactured by Bristol-Myers Squibb Co. Carvedilol phosphate are extended-release capsules and used for once-daily use. Fexofenadine hydrochloride are sweetened raspberry flavored oral suspension from Sanofi-Aventis...

  • Pharma considers personalization, competition into drug costs. Kaltwasser, Jared // njbiz;2/6/2012, Vol. 25 Issue 6, p16 

    The article reports on the efforts of several pharmaceutical firms like Bristol-Myers Squibb and Sanofi to launch cancer drugs with costs in a similar price range. M.D. Becker Partners founder Michael D. Becker said higher prices should not be qualified as a negative trend. He added that the...

  • BMS, Sanofi stage $40 mil. roster fight for Plavix DTC. Kim, Hank // Adweek Eastern Edition;3/9/1998, Vol. 39 Issue 10, p5 

    Announces the four advertising agencies in the United States which have emerged as finalists in a review for the estimated $40 million direct-to-consumer advertising launch of Plavix prescription heart attack and stroke preventive product co-marketed by Bristol-Myers Squibb and Sanofi.

  • Cancer News Round-up.  // PharmaWatch: Cancer;Oct2005, Vol. 4 Issue 10, p2 

    Focuses on recent developments related to oncology. Approval gained by Pfizer Inc. to market its breast cancer drug Aromasin in New Zealand, Switzerland and other European countries; Information about a recent study comparing Sanofi-Aventis SA's breast cancer drug Taxotere to Bristol-Myers...

  • Sanofi-Aventis/Apotex: olive branch acceptance to reduce generic threat.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p14 

    The article reports on the agreement of Sanofi-Aventis and Bristol-Myers Squibb Co. to settle a patent infringement suit with Canadian generics maker Apotex over the anti-platelet agent Plavix. The settlement should delay the generic threat to Plavix as well as to enable the companies to avoid...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics